Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey. Renal involvement in sarcoidosis.

Main Article Content

Francesco Rastelli
Ivano Baragetti
Laura Buzzi
Francesca Ferrario
Luisa Benozzi
Francesco Di Nardo
Elisabetta Devoti
Giovanni Cancarini
Nicoletta Mezzina
Pietro Napodano
Maurizio Gallieni
Domenico Santoro
Michele Buemi
Paola Pecchini
Fabio Malberti
Valeriana Colombo
Giacomo Colussi
Ettore Sabadini
Giuseppe Remuzzi
Lucia Argentiero
Loreto Gesualdo
Guido Gatti
Francesco Trevisani
Giorgio Slaviero
Donatella Spotti
Olga Baraldi
Gaetano La Manna
Eugenia Pignone
Marco Saltarelli
Marco Heidempergher
Michela Tedesco
Augusto Genderini
Michela Ferro
Cristiana Rollino
Dario Roccatello
Gabriella Guzzo
Roberta Clari
Giorgina Piccoli
Cristina Comotti
Giuliano Brunori
Paolo Cameli
Elena Bargagli
Paola Rottoli
Mauro Dugo
Maria Cristina Maresca
Massimo Bertoli
Morena Giozzet
Rachele Brugnano
Emidio Giovanni Nunzi
Marco D'Amico
Claudio Minoretti
Irene Acquistapace
Carla Colturi
Ernesto Minola
Mario Camozzi
Antonella Tosoni
Manuela Nebuloni
Franco Ferrario
Giacomo Dell'Antonio
Stefano Cusinato
Sandro Feriozzi
Claudio Pozzi



Background: Granulomatous interstitial nephritis in sarcoidosis (sGIN) is generally clinically silent, but in <1% causes acute kidney injury (AKI). Methods: This Italian multicentric retrospective study included 39 sarcoidosis-patients with renal involvement at renal biopsy: 31 sGIN-AKI, 5 with other patterns (No-sGIN-AKI), 3 with nephrotic proteinuria. We investigate the predictive value of clinical features, laboratory, radiological parameters and histological patterns regarding steroid response. Primary endpoint: incident chronic kidney disease (CKD) beyond the 1°follow-up (FU) year; secondary endpoint: response at 1°line steroid therapy; combined endpoint: the association of initial steroid response and outcome at the end of FU. Results: Complete recovery in all 5 No-sGIN-AKI-patients, only in 45% (13/29) sGIN-AKI-patients (p=0.046) (one lost in follow-up, for another not available renal function after steroids). Nobody had not response. Primary endpoint of 22 sGIN-AKI subjects: 65% (13/20) starting with normal renal function developed CKD (2/22 had basal CKD; median FU 77 months, 15–300). Combined endpoint: 29% (6/21) had complete recovery and final normal renal function (one with renal relapse), 48% (10/21) had partial recovery and final CKD (3 with renal relapse, of whom one with basal CKD) (p=0.024). Acute onset and hypercalcaemia were associated to milder AKI and better recovery than subacute onset and patients without hypercalcaemia, women had better endpoints than men. Giant cells, severe interstitial infiltrate and interstitial fibrosis seemed negative predictors in terms of endpoints. Conclusions: sGIN-AKI-patients with no complete recovery at 1°line steroid should be treated with other immunosuppressive to avoid CKD, in particular if males with subacute onset and III stage-not hypercalcaemic AKI.


Download data is not yet available.
Abstract 111 | PDF Downloads 71


1. Baughman RP, Lower EE, Du Bois RM. Sarcoidosis. Lancet 2003; 361(9363):1111-1118.
2. Adams DO. The granulomatous inflammatory response. A review. Am J Pathol 1976; 84(1):164-192.
3. Valeyre D, Nunes H, Bernaudin JF. Advanced pulmonary sarcoidosis. Curr Opin Pulm Med 2014; 20(5):488-495.
4. Calender A, Jeny F, Nunes H. Sarcoidosis [Internet]. Orphanet: The portal for rare diseases and orphan drugs. [quoted on 19 March 2021]. Available on:
5. Tinelli C, De Silvestri A, Richeldi L, Oggionni T. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:S4-8.
6. Beghè D, Dall’Asta L, Garavelli C, Pastorelli AA, Muscarella M, Saccani G, et al. Sarcoidosis in an Italian province. Prevalence and environmental risk factors. PloS one. 2017;12(5):e0176859.
7. European Commission Report. Useful information on rare diseases from an EU perspective. Retrieved 19 May 2009.
8. Brito-Zeron P, Kostov B, Superville D, Baughman RP, Ramos-Casals M. Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. Clin Exp Rheumatol. 2019;37(6):1052–64.
9. Schupp JC , Freitag-Wolf S , Bargagli E , et al. Phenotypes of organ involvement in sarcoidosis. Eur Respir J 2018; 51:170099.
10. Longcope WT, Freiman DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore) 1952; 31(1):1-132.
11. Javaud N, Belenfant X, Stirnemann J, Laederich J, Ziol M, Callard P, et al. Renal granulomatoses: a retrospective study of 40 cases and review of the literature. Medicine. 2007;86(3):170–80.
12. Bijol V, Mendez GP, Nose V, Rennke HG. Granulomatous interstitial nephritis: a clinicopathologic study of 46 cases from a single institution. International Journal of Surgical Pathology. 2006;14(1):57–63.
13. Bagnasco SM, Gottipati S, Kraus E, Alachkar N, Montgomery RA, Racusen LC, et al. Sarcoidosis in native and transplanted kidneys: incidence, pathologic findings, and clinical course. PLoS One. 2014;9(10):e110778.
14. Löffler C, Löffler U, Tuleweit A, Waldherr R, Uppenkamp M, Bergner R. Renal sarcoidosis: epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis Vasc Diffuse Lung Dis 2015; 31(4):306-315.
15. Mahévas M, Lescure FX, Boffa J-J, Delastour V, Belenfant X, Chapelon C, et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine. 2009;88(2):98–106.
16. Simerville JA, Maxted WC, Pahira JJ. Urinalysis: a comprehensive review. Am Fam Physician. 2005 Mar 15;71(6):1153-62. Erratum in: Am Fam Physician. 2006 Oct 1;74(7):1096. PMID: 15791892.
17. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney international. 2014;85(1):49–61.
18. Kdigo A. Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
19. Kamata Y, Sato H, Joh K, Tsuchiya Y, Kunugi S, Shimizu A, et al. Clinical characteristics of biopsy-proven renal sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis 2018;35(3):252.
20. Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic utility of angiotensin#converting enzyme in sarcoidosis: a population-based study. Lung. 2016;194(1):91–5.
21. Bunting PS, Szalai JP, Katic M. Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem. 1987;20(3):213–9.
22. Niederer RL, Al-Janabi A, Lightman SL, Tomkins-Netzer O. Serum angiotensin-converting enzyme has a high negative predictive value in the investigation for systemic sarcoidosis. Am J Ophthalmol. 2018;194:82–7.
23. Ramos-Casals M, Retamozo S, Sisó-Almirall A, Pérez-Alvarez R, Pallarés L, Brito-Zerón P. Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. Expert Rev Clin Immunol. 2019;15(4):391–405.
24. Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev. 2016 May;37(2):85-98. PMID: 28303073; PMCID: PMC5198510.
25. Rajakariar R, Sharples E, Raftery M, Sheaff M, Yaqoob M. Sarcoid tubulo-interstitial nephritis: long-term outcome and response to corticosteroid therapy. Kid int. 2006;70(1):165–9.
26. Berliner AR, Haas M, Choi MJ. Sarcoidosis: The Nephrologist’s Perspective. Am J Kid Dis 2006; 48(5): 856-870.
27. Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20(2):126-132.
28. Sanada S, Yoda S, Sato T. Pathological value of lysozyme staining for renal sarcoidosis. Nephrology Dialysis Transplantation. 2020;35(9):1638–41.
29. Patel TV, Rennke HG, Sloan JM, DeAngelo DJ, Charytan DM. A forgotten cause of kidney injury in chronic myelomonocytic leukemia. Am J Kid Dis 2009;54(1):159–64.
30. Iannuzzi MC, Rybicki BA, Teirstein AS. Medical progress. Sarcoidosis. N Eng J Med. 2007;357:2153–65.
31. Toriu N, Sumida K, Oguro M, Oshima Y, Mizuno H, Hasegawa E, et al. Increase of 1, 25 dihydroxyvitamin D in sarcoidosis patients with renal dysfunction. Clin Exp Nephrol. 2019;23(10):1202–10.
32. Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev. 2016; 37(5):521–47.
33. Baughman R, Janovcik J, Ray M, Sweiss N, Lower E. Calcium and vitamin D metabolism in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis. 2013; 30(2):113–20.
34. Derose SF, Rutkowski MP, Crooks PW, Shi JM, Wang JQ, Kalantar-Zadeh K, et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis. 2013;62(2):236–44.
35. Peralta CA, Katz R, DeBoer I, Ix J, Sarnak M, Kramer H, et al. Racial and ethnic differences in kidney function decline among persons without chronic kidney disease. J Am Soc Nephrol 2011;22(7):1327–34.
36. Baba M, Shimbo T, Horio M, Ando M, Yasuda Y, Komatsu Y, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS One. 2015;10(6):e0129036.
37. Wetzels J, Kiemeney L, Swinkels D, Willems H, Den Heijer M. Age-and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 2007;72(5):632–7.
38. Koraishy FM, Hooks-Anderson D, Salas J, Rauchman M, Scherrer JF. Fast GFR decline and progression to CKD among primary care patients with preserved GFR. Int Urol Nephrol. 2018;50(3):501-508.
39. Krolewski AS, Skupien J, Rossing P, Warram JH . Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 2017;91(6):1300–11.
40. Zissel G, Prasse A, Muller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31(4):390-403.
41. Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol 2017; 24(1):59-65.
42. Ueda S, Murakami T, Ogino H, Matsuura M, Tamaki M, Kishi S, et al. 2 Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions. Internal Medicine. 2019;58(5):679–84.
43. Mortaz E, Rezayat F, Amani D, Kiani A, Garssen J, Adcock IM, et al. The Roles of T Helper 1, T Helper 17 and Regulatory T Cells in the Pathogenesis of Sarcoidosis. Iran J Allergy Asthma Immunol. 2016; 15(4):334-339.
44. Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110(6):774-802.
45. Bergantini L, Bianchi F, Cameli P, Mazzei MA, Fui A, Sestini P, et al. Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6. Dis Markers. 2019 Mar 3; 2019:8565423. doi: 10.1155/2019/8565423. eCollection 2019.
46. Mañá J, Rubio-Rivas M, Villalba N, Marcoval J, Iriarte A, Molina-Molina M, et al. Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain. Medicine 2017; 96:29(e7595).
47. Hilderson I, Van Laecke S, Wauters A, Donck J. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. Nephrol Dial Transplant 2014; 29(10):1841-1847.
48. Sauer WH, Stern BJ, Baughman RP, Culver DA, Royal W. High-Risk Sarcoidosis. Current Concepts and Research Imperatives. Ann Am Thorac Soc 2017; 14(Supplement_6):S437-S444.
49. Rossman MD, Newman LS, Baughman RP, Teirstein A, Weinberger SE, Miller Jr W, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23(3):201-208.
50. Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, et al. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31(1):46-54.

Most read articles by the same author(s)